Mon, Dec 22, 2014, 8:03 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Jun 18, 2009 1:53 PM Flag

    back to 66 cents

    I liked that one.

    So we are both in it for a better deal than 15% and 10 million as upfront? It's just so hard waiting?

    The IDIS agreement must be painful for you.

    Or - Do you acctually admit that if a sellforce of Epicept sells 3000 Ceplene treatments in Europe the BP could never - never - sell for a higher net revenue than Epicept taking the gross them selfs, given the limitation of the new patient group each year (16 000)? Using your figures (15%) as assumtions.

    How will your next post about the dilution gost look like?

    I'll give you a clue: You have to show that the IDIS agreement given a life safing drug with exclusive rights on the market will not reach the market. My figures of at least 100 new treatments each month is all wrong.

    I hope this discussion might be seen as a metaphor for the negotiations and where the energy is right now.

    In broken English,

1.99-0.04(-1.97%)Dec 22 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Henry Schein, Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Sirona Dental Systems Inc.
NASDAQMon, Dec 22, 2014 3:59 PM EST